Amivantamab

CAS 2171511-58-1 0 current recordsBiologic

Who holds supplier records for Amivantamab? No organisation holds a current US Type II DMF or EU CEP for Amivantamab in the registers PharmaTek covers.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 12 Nov 2026. How we read these records

Cite as: PharmaTek, “Amivantamab: DMF and CEP holder records”, record as of 12 Nov 2026, pharmatek.co.uk/directory/api/amivantamab

Reading the evidence

  • No current DMF or CEP on record

    The covered registers hold no supplier record for this substance. This is not evidence that no one makes it: suppliers may file under another name, sell outside the US and EU, or use an ASMF.

Current records (0)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Amivantamab. Country is the organisation's recorded country, not necessarily the manufacturing site.

Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.

Need Amivantamab sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Overview

Amivantamab is a monoclonal antibody designed to target EGFR and MET receptors, used in the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations. It works by inhibiting tumor growth and promoting immune cell-mediated cytotoxicity.

Therapeutic areas

Oncology

Record history

PharmaTek records which organisations hold a current DMF or CEP for Amivantamab every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.
For suppliers

Do you supply Amivantamab?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.